Cholesterol trafficking from the outer to the cholesterol-poor inner mitochondrial membrane requires energized, polarized and actively respiring mitochondria, mediated by a highly regulated multimeric (140-200 kDa) protein complex comprising StAR (steroidogenic acute regulatory protein), mitochondrial TSPO (translocator protein), VDAC (voltage-dependent anion channel), ANT (adenine nucleotide transporter) and associated regulatory proteins. Mitochondrial cholesterol transport is rate-limiting in the CYP27A1 (sterol 27-hydroxylase)-dependent generation of oxysterol ligands for LXR (liver X receptor) transcription factors that regulate the expression of genes encoding proteins in the cholesterol efflux pathway, such as ABC transporters (ATP-binding cassette transporters) ABCA1 and ABCG1. These transporters transfer cholesterol and/or phospholipids across the plasma membrane to (apo)lipoprotein acceptors, generating nascent HDLs (high-density lipoproteins), which can safely transport excess cholesterol through the bloodstream to the liver for excretion in bile. Utilizing information from steroidogenic tissues, we propose that perturbations in mitochondrial function may reduce the efficiency of the cholesterol efflux pathway, favouring accumulation of cholesteryl ester 'foam cells' and allowing the toxic accumulation of free cholesterol at the interface between the endoplasmic reticulum and the mitochondrial membrane. In turn, this will trigger opening of the permeability transition pore, allowing unregulated production of oxysterols via CYP27A1, allowing the accumulation of esterified forms of this oxysterol within human atherosclerotic lesions. Defective cholesterol efflux also induces endoplasmic reticulum stress, proteasomal degradation of ABCA1 and Fas-dependent apoptosis, replicating findings in macrophages in advanced atherosclerotic lesions. Small molecules targeted to mitochondria, capable of sustaining mitochondrial function or improving cholesterol trafficking may aid cholesterol efflux from macrophage 'foam' cells, regressing and stabilizing the atherosclerotic plaque.
INTRODUCTION
The importance of macrophage cholesterol efflux, and the reverse cholesterol transport pathway, in protecting against atherosclerosis and coronary heart disease is highlighted by epidemiological studies in humans and in genetically modified mice in which components of this pathway have been overexpressed or deleted [1] [2] [3] [4] . Elimination of excess cholesterol from macrophage 'foam' cells remains a key anti-atherosclerotic strategy and can be achieved, in vivo and in vitro, by cellular cholesterol efflux, orchestrated by ABC transporters (ATP-binding cassette transAbbreviations: ABC transporter, ATP-binding cassette transporter; ACBD, acyl-CoA-binding domain-containing; ANT, adenine nucleotide transporter; apoA etc., apolipoprotein A etc.; CTX, cerebrotendinous xanthomatosis; HDL, high-density lipoprotein; IL-1, interleukin-1; LDL, low-density lipoprotein; LXR, liver X receptor; m , mitochondrial membrane potential; mtHSP70, mitochondrial heat-shock protein 70; PBR, peripheral benzodiazepine receptor; PKA, protein kinase A; PKB, protein kinase B; PKC, protein kinase C; PTP , permeability transition pore; ROS, reactive oxygen specie; RXR, retinoic acid receptor; StAR, steroidogenic acute regulatory protein; TSPO , translocator protein; VDAC, voltage-dependent anion channel.
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porters), such as ABCA1, ABCG1 and ABCG4, and 'acceptor' (apo)lipoproteins, such as apoA-I, apoE and HDLs (high-density lipoproteins) [1] [2] [3] [4] [5] [6] . Notably, ABCA1 promotes efflux of phospholipids and cholesterol to lipid-poor acceptors, such as apoA-I and apoE, whereas ABCG1 and ABCG4 promote efflux of cholesterol, oxysterols and/or desmosterol to HDL [4, 5] , so that these transporters work in concert to generate HDL, which enters and matures within the reverse cholesterol transport pathway, delivering excess cholesterol to the liver for excretion in bile.
Ligand activation of nuclear LXRs (liver X receptors) (LXRα/β) is pivotal in cellular responses to elevated sterol content, triggering cholesterol efflux mechanisms: both synthetic and oxysterol LXR agonists potently up-regulate ABCA1 and ABCG1 gene expression [6] [7] [8] [9] . LXRs form heterodimers with RXRs (retinoic acid receptors) bound to an imperfect direct repeat of the nuclear receptor half-site TGACCT, separated by four bases (DR-4) [7] . In addition, LXRα regulates cholesterol biosynthesis via novel negative LXR DNA-response elements within the promoter region of CYP51A1 (lanosterol 14α-demethylase) and squalene synthase [10] , and can suppress uptake of LDL (low-density lipoprotein) by transcriptional induction of the E3 ubiquitin ligase Idol (inducible degrader of the LDL receptor) [11] . Oxysterols can also sequester SREBPs (sterol-regulatoryelement-binding proteins) at the endoplasmic reticulum by binding to Insig, resulting in co-ordinated repression of cholesterol biosynthesis and uptake under conditions of sterol excess [10] . Finally, although LXRs can also transrepress genes involved in the inflammatory response, via a mechanism involving NCoR (nuclear receptor co-repressor), SMRT (silencing mediator of retinoid and thyroid receptors) and inhibition of NF-κB (nuclear factor κB) signalling [12] , this response appears ligand-specific, so that some oxysterols, such as 27-hydroxycholesterol, made at relatively high levels by cultured macrophages (see below) appear not to transrepress inflammatory mediators [13] . As expected, gene deletion of LXRα in the apoE − / − murine model of atheroma resulted in cholesterol accumulation in peripheral tissues and accelerated atherosclerosis, whereas deletion of both isoforms in wild-type mice elicited lipid accumulation in foam cells within the aortic root, even in the absence of an atherogenic stimulus (reviewed in [13] ).
Potential sources of oxysterol ligands for LXRs within the arterial wall include those provided by uptake of oxidized LDL [11] [12] [13] , oxysterols derived by trafficking cholesterol to CYP27A1 (sterol 27-hydroxylase), located on the inner mitochondrial membrane [13] , and those generated via cholesterol biosynthetic pathways, such as 24(S), 25-epoxycholesterol [10, 11] . However, the major oxysterols present in oxidized LDL, non-enzymically generated 7-keto-and 7-β-hydroxycholesterol, do not bind LXRα [6, 7] , whereas the impact of 24(S), 25-epoxycholesterol is lost in cholesterol-enriched macrophage 'foam cells', reflecting profound repression of cholesterol biosynthesis [11] . By contrast, human macrophages express high levels of CYP27A1, which can produce a variety of modified sterols, all of which have been cited as LXRα ligands [6, [14] [15] [16] [17] [18] . Crucially, Chen et al. [17] have confirmed that 24-, 25-and 27-hydroxycholesterol are LXR ligands in vivo, using oxysterol inactivation and multiple genetic deletion studies in mice.
Overexpression of CYP27A1 leads to increased cellular efflux of cholesterol, although not necessarily via induction of ABCA1 [18, 19] . Fu et al. [18] demonstrated that overexpression of CYP27A1 induces ABCG1 in HEK (human embryonic kidney)-293 cells [18] , whereas Escher et al. [19] showed that CYP27A1 overexpression in CHO (Chinese-hamster ovary) cells inhibited cholesterol biosynthesis and increased efflux without affecting the expression or abundance of ABCA1 [19] . However, Fu et al. [18] also demonstrated ablation of ABCA1 induction in response to cholesterol loading of CYP27A1-deficient human fibroblasts. Since then, the production of 27-hydroxycholesterol has been directly linked with activation of LXRα and induction of ABCA1 mRNA and protein in macrophages [20, 21] , endothelial cells [22] , enterocytes [23, 24] and neurons [25] . These differences may represent cell-specific responses to overexpression of CYP27A1 or reflect the highly regulated post-transcriptional regulation of ABCA1 [4, 5] . Notably, murine macrophages depleted of the Niemann-Pick C1 protein [26] and human fibroblasts with cholesteryl ester storage disease [27] are both associated with loss of 27-hydroxycholesterol production, impaired up-regulation of ABCA1 and/or ABCG1 and reduced cholesterol efflux to apolipoprotein acceptors.
In hepatocytes, CYP27A1 is responsible for the alternative 'acidic' pathway for generation of bile acid [28] , whereas in extrahepatic tissues the activity of this enzyme appears to serve two functions: the first to generate oxysterol ligands for LXRs (see above), and the second to provide a route by which macrophages and other peripheral cells can rid themselves of excess cholesterol in the absence of (apo)lipoprotein acceptors [29] . CYP27A1 encoded by its gene on chromosome 2q35, is a cytochrome P450 enzyme consisting of a 498-amino-acid mature protein and a 33-amino-acid mitochondrial signal sequence, with established adrenodoxin (residues 351-365) and haem-binding sites (residues 435-464) (reviewed in [30] ). These regions interact with two protein cofactors, adrenodoxin and adrenodoxin reductase, mediating electron transfer from NADPH and aiding oxidation of the cholesterol side chain [30] . The autosomal-recessive disorder, CTX (cerebrotendinous xanthomatosis) [30, 31] , an inherited lipid storage disease, is caused by the inactivity or absence of CYP27A1. It is clear that numerous mutations in CYP27A1 can give rise to a large variety of phenotypic expression, which can even vary within the same family. Indeed, Javitt [16] suggests that local events in specific tissues may be important determinants of phenotype. Thus, although the phenotype of CTX is complex and cannot be reproduced by genetic deletion in mice [32] , patients feature accumulation of cholesterol and cholestanol in tissues, progressive neurological deterioration and, as a secondary complication in an estimated 10 % of patients, suffer from accelerated atherosclerosis [16, 30, 31] .
It may be puzzling to note that 27-hydroxycholesterol is the major modified form of cholesterol in human atheroma [33, 34] . Surely then, if the hypothesis we propose is correct, either source of oxysterol (see above) would activate LXRα, enhancing cholesterol efflux and preventing lipid accumulation within the vessel wall? One explanation may be that it is the flux of cholesterol via CYP27A1, rather than the total cellular level of this oxysterol, that is important in regulating macrophage cholesterol efflux. If so, regulation of the rate of cholesterol transfer to CYP27A1 is a critical step in the generation of a key cell signalling molecule, the potency and activity of which can subsequently be moderated by sulfation via SULT2B1b (sulfotransferase family cytosolic 2B member 1) [17] , esterification via acyl CoA:cholesterol acyl transferase [34] or subsequent metabolism to soluble bile acid derivatives [29, 35] . Indeed, delivery of cholesterol to the inner mitochondrial membrane, presumably via the mitochondrial cholesterol trafficking complex, has been proven to be rate-limiting in controlling the activity of CYP27A1 [28] . Role of mitochondrial function in cholesterol trafficking across mitochondrial membranes Electrons (e − ) from NADH and FADH 2 pass sequentially through complex I and complex II, and then to complex III, via ubiquinol (UQ): cytochrome c (Cyt c) transfers electrons from complex III to complex IV, reducing oxygen to water. The flow of electrons is accompanied by proton (H + ) transfer across the inner mitochondrial membrane (complexes I, III and IV), creating the electrochemical gradient ψ m . Re-entry of protons to the mitochondrial matrix through complex V utilizes the protonmotive force to generate ATP from ADP and P i ; the same protonmotive force also drives the exchange of ATP for ADP via ANT. ANT also forms part of the mitochondrial cholesterol trafficking complex at contact sites between the outer (OMM) and inner (IMM) mitochondrial membranes, facilitated by interactions with VDAC and the 18 kDa TSPO. In steroidogenic tissues, after stimulation with gonadotropin hormones and/or elevation of cAMP , a 'transduceome' complex (reviewed comprehensively in [34 -37] ) is generated, with the association of ACBD3 and ACBD1, together with the regulatory subunit of PKA (PKA-R1α) and StAR. This complex traffics cholesterol from the outer to the inner (cholesterol-poor) mitochondrial membrane for conversion into pregnenolone by the action of CYP11A1, in combination with adrenodoxin (Adx) and adrenodoxin reductase (AdxR), and using NADPH as cofactor. The same complex may traffic cholesterol to CYP27A1/Adx/AdxR in macrophages and endothelial cells within the artery wall, producing oxysterol ligands for LXRα, capable of inducing genes involved in the cholesterol efflux pathway.
By contrast, the pathological response to excess free cholesterol accumulating at the interface between the endoplasmic reticulum and the mitochondrial membrane is endoplasmic reticulum stress, proteasomal degradation of ABCA1 protein [36] and opening of the mitochondrial PTP (permeability transition pore), which is closely associated with the mitochondrial cholesterol trafficking complex. Access to CYP27A1 may then be unregulated or 'uncoupled' from the mitochondrial cholesterol trafficking machinery, allowing uncontrolled flux of cholesterol to CYP27A1. In turn, this might allow larger amounts of oxysterol to be formed, leading to esterification of this molecule: over 85 % of the 27-hydroxycholesterol found within human atherosclerotic lesions is esterified and therefore incapable of activating LXRα [34] . Once this protective pathway is overwhelmed, further mitochondrial damage, apoptosis and cytotoxicity may ensue, all features associated with the exogenous addition of oxysterols in micromolar quantities to cultured cells [37] .
COMPONENTS OF THE MITOCHONDRIAL CHOLESTEROL TRAFFICKING MACHINERY: LESSONS FROM STEROIDOGENIC TISSUES
Trafficking of cholesterol from the outer to the cholesterol-poor inner mitochondrial membrane is established as the rate-limiting step in provision of cholesterol substrate to the cytochrome P450 side-chain cleavage enzyme (P450scc; CYP11A1) responsible for production of pregnenolone, the common precursor for synthesis of steroid hormones in steroidogenic tissues [38] . This process is also the rate-limiting step governing the activity of CYP27A1 [29] , responsible for generating 27-oxygenated derivatives of cholesterol (see above) ( Figure 1 ).
The current model by which cholesterol is transferred to the inner mitochondrial membrane involves a basal complex, which forms at contact sites between the outer and inner mitochondrial membranes, composed of the 18 kDa TSPO [translocator protein; formerly called PBR (peripheral benzodiazepine receptor)], VDAC (voltage-dependent anion channel) and ANT (adenine nucleotide transporter) (reviewed in [39] ). In steroidogenic tissues, following acute hormonal stimulation, a 'transducesome' complex is formed in which TSPO and VDAC recruit the regulatory subunit of PKA (protein kinase A) (PKA-R1α) which binds to ACBD3 [acyl-CoA-binding domain-containing 3), also called PAP7 (PBR/PKA-R1α-associated protein 7)] and ACBD1 [39] . Elevated levels of cAMP then release PKA catalytic subunits to phosphorylate StAR (steroidogenic acute regulatory protein) at the outer mitochondrial membrane; import of both StAR and cholesterol to the inner mitochondrial membrane and matrix occurs with the assistance of TSPO and its endogenous ligand DBI (diazepam binding inhibitor; ACBD1), thereby allowing proteolytic processing of StAR and conversion of cholesterol into pregnenolone [39] . Importantly, loss of StAR induces congenital lipoid hyperplasia in humans, whereas genetic deletion of TSPO is embryonic-lethal, highlighting the importance of these proteins in cellular sterol metabolism [39] .
Recent work suggests an equivalent role for StAR in mitochondrial cholesterol trafficking to CYP27A1, in human and murine macrophages, with expression of StAR observed in human monocytes, THP-1 macrophages and human aortic tissue [40] . Notably, gene expression of StAR is repressed in macrophages exposed to oxidized LDL [40] , whereas overexpression of this protein can decrease macrophage lipid content, repress inflammation [41] and increase the efficiency of macrophage cholesterol efflux [41, 42] , via a mechanism dependent upon LXRα activation and CYP27A1 activity [41] . Tail vein injection of a viral vector expressing StAR reduced hepatic, aortic and serum lipid content, and limited atheroma in apoE − / − mice [43] . The involvement of the other components of the cholesterol trafficking complex in the regulation of macrophage cholesterol efflux has yet to be established, but may arguably be intuited, given their expression in a wide range of non-steroidogenic tissues [39] .
Thus the current evidence points to a model whereby mitochondrial cholesterol trafficking, mediated by the StAR-TSPO protein complex, determines the rate of CYP27A1 generation of the LXR ligand 27-hydroxycholesterol, controlling the expression of genes and proteins involved in anti-atherogenic efflux of cholesterol to lipid poor (apo)lipoproteins.
MITOCHONDRIAL (DYS)FUNCTION AND CHOLESTEROL TRAFFICKING TO MITOCHONDRIAL CYTOCHROME P450 ENZYMES: IMPACT ON CHOLESTEROL EFFLUX?
It is evident that steroidogenesis is highly sensitive to perturbed mitochondrial function [44, 45] , and clearly sustained production of ATP is needed to fuel the activity of ABC transporters involved in cholesterol efflux. However, studies using established pharmacological agents which disrupt mitochondrial function have indicated that energized, polarized and actively respiring mitochondria are required to sustain mitochondrial cholesterol transport and steroid hormone biosynthesis [44, 45] . Dissipation of the m (mitochondrial membrane potential) using carbonyl CCCP (carbonyl cyanide m-chlorophenylhydrazone) inhibited progesterone formation in Leydig cells, without affecting the synthesis of StAR, although import and proteolytic processing of StAR within mitochondria was lost [44] . By contrast, antimycin A, which prevents electron transport by interfering with Complex III, inhibited both steroidogenesis and reduced levels of StAR protein [44, 45] (Figure 2 ). Reduction of pH using nigericin reduced both progesterone formation and StAR protein, whereas the F 1 -F 0 ATP synthase inhibitor oligomycin, which reduces cellular levels of ATP, achieved the same outcome [44, 45] . Overall, the results indicated that m , ATP synthesis and pH were all required for acute synthesis of steroid hormones and that disruption of the protonmotive force may inhibit the efficiency of mitochondrial cholesterol transfer. Furthermore, ROS (reactive oxygen species), either exogenously or endogenously derived, can disrupt steroidogenesis and inhibit the expression of StAR in Leydig cells: these effects are associated with disruption of m , activation of the p38 MAPK (mitogen-activated protein kinase) and c-Jun signalling pathways, and suppression of Nur77 transactivation, one of the major transcription factors involved in regulating the expression of steroidogenic enzymes [46] [47] [48] .
It remains an open and key question as to whether perturbations in mitochondrial function, a key element of atheroma development, has an impact in the same way on the expression and/or activity of the mitochondrial protein complex involved in Figure 3 Putative 'mitoprotective' mechanisms which might sustain or improve mitochondrial cholesterol trafficking Complex I leaks electrons to the matrix, allowing production of the superoxide anion (O 2 − ), whereas complex III can leak electrons to both the intermembrane space and the matrix, generating O 2 − at both sites. These damaging ROS can be dismutated to H 2 O 2 by Cu,Zn SOD in the intermembrane space, and by SOD2 (superoxide dismutase 2) in the matrix, with H 2 O 2 reduced to water by glutathione peroxidase (GPX), and oxidized glutathione (GSSG) back to reduced glutathione (GSH) by glutathione reductase. Together, these enzymes can protect the respiratory chain, and mitochondrial DNA, from damage associated with mitochondrial oxidative stress. By contrast, the p66
Shc protein can subtract electrons from cytochrome c to form superoxide, thereby increasing ROS production, inducing cytochrome c release, dissipating membrane potential and triggering apoptosis. This can be prevented by sequestering p66
Shc as a higher molecular mass complex, associated with MtHSP70. Other 'mitoprotective' mechanisms might involve targeting antioxidants, such as MitoQ, to the inner mitochondrial membrane or enhancing the function of the cholesterol trafficking complex, using agents known to induce the expression and/or activity of StAR (gonadotropins and cAMP), TSPO (PKA, PKC and IL-1) and selective TSPO ligands. Alternatively, activation of cell survival pathways, mediated by PKB/Akt, induce the association of hexokinase II (HKII) with the mitochondrial TSPO protein complex, improving mitochondrial function and preventing apoptosis. Adx, adrenodoxin; AdxR, adrenodoxin reductase.
transport of cholesterol to CYP27A1 in human macrophages and endothelial cells, although it is clear that some of the same pathways can influence macrophage cholesterol efflux (Figure 3 ) [41] [42] [43] . Many factors regulate the expression, activity and phosphorylation status of StAR in steroidogenic tissues, including cAMP, gonadotropins, cytokines and growth factors [39] . Equally, the expression of TSPO is markedly regulated in a number of differing disease states, including atherosclerosis, and the activity of this protein can be targeted pharmacologically using selective and specific TSPO ligands [49] , which are currently under development for a number of differing disease conditions. Tissue-specific cell signalling strategies targeting the TSPO protein complex might be envisaged, such as regulation by PKA, PKC (protein kinase C) or IL-1 (interleukin-1), which have been shown to up-regulate TSPO and impart cellular protection against ROS, at least at physiological levels [49] . High levels of ROS are linked to reduced TSPO expression, cytochrome c leakage and cell death, via opening of the mitochondrial PTP [49] , which may allow overt and unregulated production of 27-hydroxycholesterol (see above), causing further mitochondrial damage and apoptosis. It may also be possible to protect the functionality of the cholesterol trafficking complex by increasing the expression of antioxidant scavenging pathways, blocking the activity of p66
Shc by binding with mtHSP70 (mitochondrial heatshock protein 70) or using strategies associated with cell survival, such as activation of the PKB (protein kinase B)/Akt pathway, which induces the association of hexokinase II with the mitochondrial TSPO protein complex, protecting against pro-apoptotic signals [50] .
A number of more general mitochondrial-targeting strategies have been described, including 'mitochondriotropic delivery devices', such as delocalized lipophilic cations, to deliver differing biologically active molecules to mitochondria [50] . For example, MitoQ, a TPP + (triphenyl-phosphonium cation)-linked derivative, has been shown to be a highly effective antioxidant, in part due to the ability of this linker to concentrate this molecule more than 100-fold within mitochondria. Other strategies to target cell-permeant antioxidants to the inner mitochondrial membrane include linkage to Szeto-Schiller peptides, colloidal drug delivery systems and by targeting the mitochondrial protein import machinery [50] .
SUMMARY
This novel hypothesis proposes that dysfunctional mitochondria, and associated components of the mitochondrial cholesterol trafficking complex located at contact sites between the outer and inner mitochondrial membranes, may be valid therapeutic targets for treatment of a number of disease conditions. Possible drug targets might include antioxidant molecules, which can sustain the respiratory function of the electron transfer chain, or more specific molecules targeted to components of the protein complex involved in cholesterol transfer, including StAR and TSPO. In turn, we predict that sustained or enhanced mitochondrial cholesterol trafficking, within physiological parameters, will increase the rate of production of oxysterol ligands for LXR/RXR heterodimers and induce the transcription of genes involved in the cholesterol efflux pathway. Loss of this protective pathway has been linked to Type 2 diabetes mellitus and atherosclerosis, with implications for a number of differing disease conditions. 
